Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CD38 | P28907 | 2/20 | 0.43 |
| ▸ | WNT1 | P04628 | 8/20 | 0.42 |
| ▸ | GSK3B | P49841 | 8/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | MARK3 | P27448 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23185433 | 0.96 | WNT1 (0.44) | MAPTCD38WNT1GSK3BDYRK1A | |
| SCHEMBL26260195 | 0.79 | DYRK1A (0.49) | MAPTCD38WNT1GSK3BDYRK1A | |
| SCHEMBL16159853 | 0.76 | DYRK1A (0.46) | MAPTCD38WNT1GSK3BDYRK1A | |
| SCHEMBL7988012 | 0.75 | CYP2A6 (0.45) | MAPTHSD11B1PIK3CBCYP2A6HTR1D | |
| SCHEMBL19903845 | 0.75 | HTR1D (0.59) | MAPTHSD11B1CYP2A6HTR1D | |
| SCHEMBL16159089 | 0.75 | DYRK1A (0.50) | CD38WNT1GSK3BDYRK1A | |
| SCHEMBL26260216 | 0.74 | DYRK1A (0.47) | MAPTCD38WNT1GSK3BDYRK1A | |
| SCHEMBL21241353 | 0.74 | CYP2A6 (0.41) | MAPTHSD11B1PIK3CBCYP2A6HTR1D | |
| SCHEMBL18029231 | 0.73 | HTR6 (0.60) | MAPTHSD11B1CYP2A6HTR1D | |
| SCHEMBL7457053 | 0.73 | CYP11B1 (0.50) | MAPTCD38WNT1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645484-B1 | METHOD FOR PREPARATION OF ALKYLATED OR FLUORO, CHLORO AND FLUOROCHLORO ALKYLATED COMPOUNDS BY HETEROGENEOUS COBALT CATALYSIS | LONZA SOLUTIONS AG (CH) | 2021-11-10 | — | — | EP | disclosed |
| US-20200157063-A1 | Method for Preparation of Alkylated or Fluoro, Chloro and Fluorochloro Alkylated Compounds by Heterogeneous Cobalt Catalysis | ARXADA AG (CH) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157063-A1 | Method for Preparation of Alkylated or Fluoro, Chloro and Fluorochloro Alkylated Compounds by Heterogeneous Cobalt Catalysis | ABL1, CAT, MYC | MAPT 3929/4885CD38 513/4885WNT1 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.